BridgeBio Pharma, Inc.

BBIONASDAQHealthcare● Active

$67.59

$-0.02(-0.03%)

Market Cap$13.2B

P/E Ratio—

52W High$84.94

52W Low$37.69

Avg Volume2.6M

Open$67.86

Beta0.97

Overview

BridgeBio Pharma, Inc. (BBIO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

BBIO · free cash flow · updated Jun 8, 2026

Core FCF metrics

BBIO · FCF · TTM · margin & CAGR

Free cash flow was −$447.0M for FY2025 (fiscal year ending 2025-12-31), up 14.3% year-over-year The FCF margin was -89.0%.

FY2025 Free Cash Flow−$447.0M▲ +14.3% YoY

Trailing 12M (TTM)−$454.1Mtrailing 4 quarters sum

FCF Margin-89.0%−$447.0M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

BBIO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$445.9M(1M)−$447.0M▲ +14.3%-89.0%

FY2024−$520.7M(1M)−$521.7M▲ +1.4%-235.1%

FY2023−$527.7M(1M)−$529.0M▼ 24.2%—

FY2022−$419.5M(6M)−$425.8M▲ +22.0%-548.4%

FY2021−$497.9M(48M)−$546.2M▼ 34.1%-783.4%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

BBIO · P/FCF · FCF yield · FCF per share

BridgeBio Pharma, Inc. (BBIO) reported negative free cash flow of −$0.45B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

BBIO · cash flow statement · operating / investing / financing

For FY2025, BridgeBio Pharma, Inc. generated −$445.9M in operating cash flow and spent 1M in capital expenditures, yielding −$447.0M in free cash flow.

Operating Activities

−$445.9M

Cash from core business operations

2025-12-31

Investing Activities

−$24.5M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$359.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$445.9M) − |CapEx| (1M) = FCF (−$447.0M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

BBIO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

BridgeBio Pharma, Inc.YOU

BBIO

−$447.0M+14.3%-89.0%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

BridgeBio Pharma, Inc. (BBIO) reported free cash flow of −$447.0M for FY2025 (fiscal year ending 2025-12-31), up 14.3% year-over-year. The FCF margin was -89.0%.

BridgeBio Pharma, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 9 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

BBIO free cash flow · 8 questions

BridgeBio Pharma, Inc. free cash flow was −$447.0M for FY2025, up 14.3% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$454.1M.

BBIO free cash flowBBIO FCFBBIO FCF 2025BBIO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · BridgeBio Pharma, Inc. · BridgeBio Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026